Johnson & Johnson $JNJ Stock Sold by Hall Laurie J Trustee

Hall Laurie J Trustee decreased its position in Johnson & Johnson (NYSE:JNJ) by 7.6% during the 3rd quarter, Holdings Channel reports. The firm owned 27,880 shares of the company’s stock after selling 2,282 shares during the period. Johnson & Johnson comprises about 2.3% of Hall Laurie J Trustee’s holdings, making the stock its 15th biggest holding. Hall Laurie J Trustee’s holdings in Johnson & Johnson were worth $7,381,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Colton Groome Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 219.1% during the third quarter. Colton Groome Financial Advisors LLC now owns 7,145 shares of the company’s stock valued at $1,892,000 after buying an additional 4,906 shares during the period. Eleva Capital SAS bought a new position in Johnson & Johnson in the third quarter worth about $1,442,000. Baker Tilly Wealth Management LLC lifted its holdings in Johnson & Johnson by 4.7% in the third quarter. Baker Tilly Wealth Management LLC now owns 10,423 shares of the company’s stock worth $2,759,000 after buying an additional 469 shares during the period. Ferguson Wellman Capital Management Inc. boosted its position in Johnson & Johnson by 41.0% during the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 666,675 shares of the company’s stock valued at $176,495,000 after acquiring an additional 193,905 shares in the last quarter. Finally, Adelphi Trust Co grew its holdings in shares of Johnson & Johnson by 5.1% during the 3rd quarter. Adelphi Trust Co now owns 1,950 shares of the company’s stock worth $516,000 after acquiring an additional 95 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: RBC Capital Markets said accelerating performance in J&J’s Innovative Medicine segment is offsetting persistent MedTech headwinds. The assessment supports the view that new drug launches and portfolio diversification can help sustain growth. Johnson & Johnson’s Innovative Medicines Momentum Offsets MedTech Headwinds
• Positive Sentiment: Analyst comparisons with Pfizer continue to favor J&J’s diversified portfolio, sales growth and new product pipeline, despite Pfizer’s lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Positive Sentiment: J&J remains attractive to income-oriented and defensive investors because healthcare demand is expected to remain relatively resilient during an economic downturn. Its long-term dividend reliability is also being highlighted in comparisons with Procter & Gamble. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: CEO Joaquin Duato said artificial intelligence should be embraced as a “force multiplier.” The comments point to potential long-term productivity and innovation benefits, but provide no near-term earnings update. Johnson & Johnson CEO Says AI Has to Be Embraced
• Negative Sentiment: MedTech’s rebound is uncertain after a second-quarter slowdown. Abiomed-related and broader competitive pressures could weigh on results, although Vision, Orthopedics and Surgery may improve in the second half. Can J&J’s MedTech Business Rebound in Q3?
• Negative Sentiment: Investors remain focused on an estimated $4 billion patent cliff in 2027. The need to replace that revenue stream could matter more than a modest quarterly earnings beat and is contributing to recent caution ahead of the report. Why a $4 Billion 2027 Patent Cliff Matters

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on JNJ shares. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research note on Wednesday, July 15th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $276.22.

Johnson & Johnson Stock Up 0.8%

Shares of Johnson & Johnson stock traded up $1.92 during midday trading on Tuesday, hitting $254.85. The company had a trading volume of 5,660,663 shares, compared to its average volume of 7,994,485. Johnson & Johnson has a 52-week low of $182.94 and a 52-week high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $614.17 billion, a P/E ratio of 29.53, a P/E/G ratio of 2.52 and a beta of 0.21. The company has a 50 day moving average of $266.10 and a 200 day moving average of $248.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the previous year, the business earned $2.77 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.